NU SKIN ENTERPRISES, INC.
Business
NU SKIN ENTERPRISES, INC. develops and distributes premium beauty and wellness products and personalized anti-aging solutions through a global consumer and sales network. Its main offerings include skincare and cosmetic products, nutritional supplements, connected beauty and wellness devices, and related personal care items marketed under brands such as Nu Skin, Pharmanex and ageLOC. The company operates a core Nu Skin business alongside Rhyz, a business arm comprising manufacturing and consumer/technology companies that support sourcing, packaging and innovation. It sells in nearly fifty markets via a direct selling model—person-to-person marketing augmented by social, digital and retail channels, with a distinct operating approach in Mainland China.
Summary from filing dated 2025-02-14
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 1,485 | 1,732 | 1,969 | 2,226 | 2,696 | |
| Cost of sales | 454 | 550 | 612 | 631 | 675 | |
| Gross profit | 1,031 | 1,182 | 1,357 | 1,595 | 2,020 | |
| Selling expenses | 508 | 652 | 742 | 880 | 1,080 | |
| General and administrative expenses | 432 | 479 | 547 | 556 | 654 | |
| Restructuring and impairment expenses | 25 | 202 | 20 | 48 | 52 | |
| Total operating expenses | 966 | 1,333 | 1,309 | 1,484 | 1,786 | |
| Operating income (loss) | 66 | −152 | 48 | 111 | 234 | |
| Interest expense | 14 | 26 | 26 | 13 | — | |
| Gain on sale | 176 | 0 | 0 | — | — | |
| Other income (expense), net | −32 | 3 | 4 | −8 | −2 | |
| Income (loss) before provision for income taxes | 196 | −175 | 27 | 89 | 232 | |
| Provision (benefit) for income taxes | 36 | −28 | 18 | −16 | 85 | |
| Net income (loss) | 160 | −147 | 9 | 105 | 147 | |
| Basic (in dollars per share) | 3.25 | −2.95 | 0.17 | 2.1 | 2.93 | |
| Diluted (in dollars per share) | 3.18 | −2.95 | 0.17 | 2.07 | 2.86 | |
| Basic (in shares) | 49 | 50 | 50 | 50 | 50 | |
| Diluted (in shares) | 50 | 50 | 50 | 51 | 51 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 239 | 187 | 256 | 265 | 340 | |
| Current investments | 1 | 11 | 12 | 14 | 15 | |
| Accounts receivable, net | 40 | 51 | 59 | 47 | 41 | |
| Inventories, net | 179 | 190 | 280 | 346 | 400 | |
| Prepaid expenses and other | 90 | 73 | 81 | 88 | 77 | |
| Current assets held for sale | 0 | 27 | 14 | — | — | |
| Total current assets | 548 | 539 | 702 | 760 | 873 | |
| Property and equipment, net | 377 | 380 | 433 | 445 | 454 | |
| Operating lease right-of-use assets | 74 | 73 | 90 | 99 | 121 | |
| Goodwill | 84 | 84 | 218 | 206 | 206 | |
| Other intangible assets, net | 43 | 74 | 95 | 67 | 77 | |
| Other assets | 280 | 298 | 248 | 244 | 175 | |
| Long-term assets held for sale | 0 | 22 | 23 | — | — | |
| Total assets | 1,405 | 1,469 | 1,809 | 1,821 | 1,906 | |
| Accounts payable | 26 | 35 | 43 | 54 | 50 | |
| Accrued expenses | 218 | 218 | 254 | 280 | 372 | |
| Current portion of long-term debt | 20 | 30 | 25 | 25 | 108 | |
| Current liabilities held for sale | 0 | 14 | 7 | — | — | |
| Total current liabilities | 264 | 297 | 329 | 359 | 530 | |
| Operating lease liabilities | 58 | 58 | 71 | 77 | 89 | |
| Long-term debt | 204 | 364 | 478 | 377 | 269 | |
| Other liabilities | 75 | 97 | 107 | 110 | 106 | |
| Long-term liabilities held for sale | 0 | 1 | 2 | — | — | |
| Total liabilities | 600 | 817 | 987 | 924 | 994 | |
| Commitments and contingencies (Notes 8 and 17) | — | — | — | — | — | |
| Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued | 91,000 | 91,000 | 91,000 | 91,000 | 91,000 | |
| Additional paid-in capital | 636 | 628 | 622 | 613 | 602 | |
| Treasury stock, at cost - 42.4 million and 40.8 million shares | −1,575 | −1,564 | −1,570 | −1,569 | −1,527 | |
| Accumulated other comprehensive loss | −116 | −125 | −100 | −87 | −74 | |
| Retained earnings | 1,860 | 1,712 | 1,870 | 1,939 | 1,912 | |
| Total stockholders' equity | 805 | 651 | 822 | 897 | 913 | |
| Total liabilities and stockholders' equity | 1,405 | 1,469 | 1,809 | 1,821 | 1,906 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 52 | 70 | 71 | 73 | 76 | |
| Non-cash lease expense | 26 | 27 | 33 | 45 | 49 | |
| Stock-based compensation | 24 | 15 | 16 | 12 | 23 | |
| Inventory write-down | 4 | 48 | 88 | 43 | 31 | |
| Foreign currency losses | 6 | 2 | 1 | 8 | 7 | |
| (Gain) loss on disposal of assets | 160,000 | −84,000 | 780,000 | 33,000 | 13 | |
| Impairment of fixed assets, goodwill and other intangibles | 25 | 181 | 0 | 10 | 32 | |
| Unrealized losses on equity investments | 28 | 0 | 0 | — | — | |
| Deferred taxes | 20,000 | −55 | −18 | −52 | 6 | |
| Accounts receivable, net | 10 | −8 | −23 | −11 | 20 | |
| Inventories, net | 12 | 30 | −13 | −3 | −127 | |
| Prepaid expenses and other | −20 | 579,000 | 6 | 3 | 15 | |
| Other assets | −9 | −1 | 45,000 | 3 | −20 | |
| Accounts payable | −9 | −7 | −10 | 9 | −13 | |
| Accrued expenses | −54 | −28 | −38 | −121 | −105 | |
| Other liabilities | 858,000 | −16 | −4 | −16 | 4 | |
| Net cash provided by operating activities | 80 | 112 | 119 | 108 | 142 | |
| Purchases of property and equipment | −34 | −42 | −58 | −59 | −69 | |
| Proceeds on investment sales | 10 | 18 | 18 | 6 | 15 | |
| Purchases of investments | 0 | −15 | −17 | −14 | −16 | |
| Acquisitions (net of cash acquired) | 0 | 0 | −77 | 0 | −19 | |
| Proceeds from sale of business, net | 194 | 0 | 0 | — | — | |
| Other, net | 1 | 0 | 0 | — | — | |
| Net cash provided by (used in) investing activities | 171 | −38 | −135 | −67 | −89 | |
| Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards | −2 | −2 | 5 | 27 | 14 | |
| Payment of cash dividends | −12 | −12 | −78 | −77 | −76 | |
| Repurchase of shares of common stock | −20 | 0 | −13 | −70 | −80 | |
| Finance lease principal payments | −2 | −3 | −3 | −2 | −2 | |
| Contingent consideration payments | 0 | −6 | 0 | 0 | — | |
| Payments on debt | −225 | −125 | −10 | −433 | −115 | |
| Proceeds from debt | 55 | 15 | 110 | 460 | 155 | |
| Other, net | 4 | 0 | 0 | — | — | |
| Net cash (used in) provided by financing activities | −202 | −133 | 11 | −100 | −105 | |
| Effect of exchange rate changes on cash | 3 | −10 | −4 | −16 | −11 | |
| Net increase (decrease) in cash and cash equivalents | 52 | −69 | −9 | −75 | −63 |